Chromogranin A regulates renal function by triggering Weibel-Palade body exocytosis

It was already known that Chromogranin A (CHGA) is released from sympathetic nerve endings and chromaffin cells. However, the role of CHGA in kidney function remained unclear. Prior research has shown that CHGA can influence endothelial cell activity. No prior work had resolved how CHGA might affect glomerular function. This gap motivated an investigation into CHGA's potential effects on renal endothelium. The knowledge gap centered on whether CHGA could influence endothelin-1 and glomerular filtration rate (GFR). That uncertainty drove the need to explore CHGA's role in renal physiology. This study aimed to clarify if CHGA could regulate kidney function through endothelial signaling.

The aim was to determine whether CHGA could influence renal function via endothelial signaling. The specific problem was to assess if CHGA could trigger endothelin-1 release and affect GFR. The motivation came from the known association between CHGA polymorphisms and ESRD risk. The study sought to explore if CHGA-endothelium interactions could explain this risk. The focus was on glomerular endothelial and mesangial cells. The goal was to test if CHGA could regulate GFR through endothelial mechanisms. The hypothesis was that CHGA could modulate renal function via endothelin-1. The study aimed to provide evidence for CHGA's role in renal physiology.

The study used cultured human umbilical vein endothelial cells to assess CHGA's effects. Researchers measured endothelin-1 release after CHGA exposure. They also tested glomerular endothelial and mesangial cell co-cultures. TGF-beta1 secretion was evaluated in mesangial cells. Plasma CHGA levels were measured in human subjects. Endothelin-1 and GFR were correlated in a clinical cohort. Genetic analysis focused on CHGA promoter haplotypes. Twin studies were used to assess GFR heritability.

CHGA triggered endothelin-1 release and Weibel-Palade body exocytosis in endothelial cells. In co-cultures, CHGA induced TGF-beta1 secretion from mesangial cells. Plasma CHGA levels correlated positively with endothelin-1 in humans. Plasma CHGA levels also correlated negatively with GFR. GFR was found to be highly heritable among twin pairs. CHGA promoter haplotypes predicted GFR levels in the study population. In hypertensive renal disease patients, a CHGA haplotype predicted GFR decline rate. These findings suggest a role for CHGA in regulating renal function.

The authors suggest that CHGA may act through glomerular endothelium to regulate renal function. The findings propose that CHGA could influence endothelin-1 and TGF-beta1 release. The study implies that CHGA may contribute to GFR regulation in humans. The data suggest that CHGA haplotypes may predict GFR decline in renal disease. The results propose that CHGA could modulate Weibel-Palade body exocytosis. The study suggests that CHGA may influence glomerular endothelial signaling. The findings propose that CHGA could impact mesangial cell activity. The authors suggest that CHGA may be a genetic factor in renal disease progression.